158 related articles for article (PubMed ID: 29957351)
21. Teaching case: a man with a progressive gait impairment and visual compromise.
Toro J; Burbano LE; Zamora A; Jones E
Mult Scler Relat Disord; 2015 Mar; 4(2):176-9. PubMed ID: 25787194
[TBL] [Abstract][Full Text] [Related]
22. Recognition performance differentiates between elderly patients in the long term course of secondary progressive multiple sclerosis and amnestic mild cognitive impairment.
Müller S; Saur R; Greve B; Melms A; Hautzinger M; Fallgatter AJ; Leyhe T
Mult Scler; 2013 May; 19(6):799-805. PubMed ID: 23166118
[TBL] [Abstract][Full Text] [Related]
23. Primary progressive multiple sclerosis: progress and challenges.
Rice CM; Cottrell D; Wilkins A; Scolding NJ
J Neurol Neurosurg Psychiatry; 2013 Oct; 84(10):1100-6. PubMed ID: 23418213
[TBL] [Abstract][Full Text] [Related]
24. Multiple sclerosis: predicting risk and delaying progression.
Yeh EA; Weinstock-Guttman B
Lancet Neurol; 2010 Jan; 9(1):7-9. PubMed ID: 20083024
[No Abstract] [Full Text] [Related]
25. The natural history of multiple sclerosis: a geographically based study 9: observations on the progressive phase of the disease.
Kremenchutzky M; Rice GP; Baskerville J; Wingerchuk DM; Ebers GC
Brain; 2006 Mar; 129(Pt 3):584-94. PubMed ID: 16401620
[TBL] [Abstract][Full Text] [Related]
26. Primary progressive multiple sclerosis presenting with severe predominant cognitive impairment and psychiatric symptoms: A challenging case.
Zambon AA; Cecchetti G; Caso F; Santangelo R; Baldoli C; Natali Sora MG; Comi G; Magnani G; Martinelli V
Mult Scler; 2017 Oct; 23(11):1558-1561. PubMed ID: 28401768
[TBL] [Abstract][Full Text] [Related]
27. Pharmacological Approaches to the Management of Secondary Progressive Multiple Sclerosis.
Nandoskar A; Raffel J; Scalfari AS; Friede T; Nicholas RS
Drugs; 2017 May; 77(8):885-910. PubMed ID: 28429241
[TBL] [Abstract][Full Text] [Related]
28. Impairment of contrast visual acuity as a functional correlate of retinal nerve fibre layer thinning and total macular volume reduction in multiple sclerosis.
Bock M; Brandt AU; Kuchenbecker J; Dörr J; Pfueller CF; Weinges-Evers N; Gaede G; Zimmermann H; Bellmann-Strobl J; Ohlraun S; Zipp F; Paul F
Br J Ophthalmol; 2012 Jan; 96(1):62-7. PubMed ID: 21378002
[TBL] [Abstract][Full Text] [Related]
29. [Retinal atrophy using optical coherence tomography (OCT) in 15 patients with multiple sclerosis and comparison with healthy subjects].
Jeanjean L; Castelnovo G; Carlander B; Villain M; Mura F; Dupeyron G; Labauge P
Rev Neurol (Paris); 2008 Nov; 164(11):927-34. PubMed ID: 18808761
[TBL] [Abstract][Full Text] [Related]
30. Human placenta-derived cells (PDA-001) for the treatment of adults with multiple sclerosis: a randomized, placebo-controlled, multiple-dose study.
Lublin FD; Bowen JD; Huddlestone J; Kremenchutzky M; Carpenter A; Corboy JR; Freedman MS; Krupp L; Paulo C; Hariri RJ; Fischkoff SA
Mult Scler Relat Disord; 2014 Nov; 3(6):696-704. PubMed ID: 25891548
[TBL] [Abstract][Full Text] [Related]
31. [Secondary progressive multiple sclerosis in childhood--interferon beta 1b treatment].
Higurashi N; Hamano S; Eto Y
No To Hattatsu; 2006 May; 38(3):209-13. PubMed ID: 16715936
[TBL] [Abstract][Full Text] [Related]
32. MRI-clinical correlations in the primary progressive course of MS: new insights into the disease pathophysiology from the application of magnetization transfer, diffusion tensor, and functional MRI.
Filippi M
J Neurol Sci; 2003 Feb; 206(2):157-64. PubMed ID: 12559504
[TBL] [Abstract][Full Text] [Related]
33. The use of multiple sclerosis condition-specific measures to inform health policy decision-making: mapping from the MSWS-12 to the EQ-5D.
Hawton A; Green C; Telford CJ; Wright DE; Zajicek JP
Mult Scler; 2012 Jun; 18(6):853-61. PubMed ID: 22108867
[TBL] [Abstract][Full Text] [Related]
34. Early accurate diagnosis crucial in multiple sclerosis.
Tur C; Thompson AJ
Practitioner; 2015 Sep; 259(1785):21-7, 2-3. PubMed ID: 26591653
[TBL] [Abstract][Full Text] [Related]
35. Assessing the validity of a computer-generated cognitive screening instrument for patients with multiple sclerosis.
Lapshin H; Lanctôt KL; O'Connor P; Feinstein A
Mult Scler; 2013 Dec; 19(14):1905-12. PubMed ID: 23652217
[TBL] [Abstract][Full Text] [Related]
36. The effectiveness of Robot-Assisted Gait Training versus conventional therapy on mobility in severely disabled progressIve MultiplE sclerosis patients (RAGTIME): study protocol for a randomized controlled trial.
Straudi S; Manfredini F; Lamberti N; Zamboni P; Bernardi F; Marchetti G; Pinton P; Bonora M; Secchiero P; Tisato V; Volpato S; Basaglia N
Trials; 2017 Feb; 18(1):88. PubMed ID: 28241776
[TBL] [Abstract][Full Text] [Related]
37. T2 lesions and rate of progression of disability in multiple sclerosis.
Mostert JP; Koch MW; Steen C; Heersema DJ; De Groot JC; De Keyser J
Eur J Neurol; 2010 Dec; 17(12):1471-5. PubMed ID: 20500805
[TBL] [Abstract][Full Text] [Related]
38. [Clinical evaluation of follow-up and disease course].
Roullet E
Rev Neurol (Paris); 2001 Sep; 157(8-9 Pt 2):1121-3. PubMed ID: 11787343
[TBL] [Abstract][Full Text] [Related]
39. Visual dysfunction in multiple sclerosis correlates better with optical coherence tomography derived estimates of macular ganglion cell layer thickness than peripapillary retinal nerve fiber layer thickness.
Saidha S; Syc SB; Durbin MK; Eckstein C; Oakley JD; Meyer SA; Conger A; Frohman TC; Newsome S; Ratchford JN; Frohman EM; Calabresi PA
Mult Scler; 2011 Dec; 17(12):1449-63. PubMed ID: 21865411
[TBL] [Abstract][Full Text] [Related]
40. Fluoxetine in progressive multiple sclerosis (FLUOX-PMS): study protocol for a randomized controlled trial.
Cambron M; Mostert J; Haentjens P; D'Hooghe M; Nagels G; Willekens B; Heersema D; Debruyne J; Van Hecke W; Algoed L; De Klippel N; Fosselle E; Laureys G; Merckx H; Van Wijmeersch B; Vanopdenbosch L; Verhagen W; Hupperts R; Hengstman G; Michiels V; Van Merhaegen-Wieleman A; De Keyser J
Trials; 2014 Jan; 15():37. PubMed ID: 24460863
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
